Introduction {#section5-2050312118801707}
============

Statins have been associated with improved survival among patients with infections,^[@bibr1-2050312118801707][@bibr2-2050312118801707][@bibr3-2050312118801707][@bibr4-2050312118801707][@bibr5-2050312118801707][@bibr6-2050312118801707]--[@bibr7-2050312118801707]^ in meta-analyses,^[@bibr8-2050312118801707],[@bibr9-2050312118801707]^ randomized trials, and observational studies.^[@bibr4-2050312118801707],[@bibr5-2050312118801707],[@bibr7-2050312118801707],[@bibr10-2050312118801707]^ The proposed pleiotropic effects with statins, including a reduced inflammatory response,^[@bibr11-2050312118801707],[@bibr12-2050312118801707]^ suggest that the critical period of exposure would be from time of onset of infection through the initial period of antibiotic therapy.^[@bibr5-2050312118801707],[@bibr10-2050312118801707],[@bibr13-2050312118801707]^ Importantly, that period of onset is likely to occur outside of the healthcare setting, and therefore there will be a delay between onset and presentation to receive care. In previous research, definitions of statin exposure vary widely between studies, tend to be overly broad, and rarely take into account statin therapy adherence.^[@bibr3-2050312118801707][@bibr4-2050312118801707]--[@bibr5-2050312118801707]^ This study sought to evaluate the impact of statin continuation during hospital admission compared with non-continuation, in a cohort of adherent statin users.

Methods {#section6-2050312118801707}
=======

A retrospective cohort study design was used to assess inpatient mortality among adherent statin users. This study was conducted using de-identified Optum Clinformatics^TM^ (OptumInsight, Eden Prairie, MN) with matched Premier Hospital data (1 October 2009--31 March 2013), which is an administrative claims database from a large commercial health plan (Optum Clinformatics) matched with hospital data (Premier). Included in the analysis were adult patients (\>18 years) with a primary diagnosis of bacteremia (International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes 003.1, 020.2, 022.3, 036.2, 038.0, 038.1, 038.10--038.12, 038.19, 038.2, 038.3, 038.40--038.44, 038.49, 038.8, 038.9, 054.5, 449, 771.81, 995.91, 995.92, and 790.7).^[@bibr14-2050312118801707]^ We only included patients with hospital admissions between 1 April 2010 and 31 March 2013, to allow for a continuous enrollment period of 6 months prior to admission. Antibiotic therapy for each patient during the hospital stay was assessed. Patients who received at least 2 consecutive days of at least one antibiotic therapy for bacteremia^[@bibr15-2050312118801707][@bibr16-2050312118801707][@bibr17-2050312118801707]--[@bibr18-2050312118801707]^ within the first 3 days of the admission were included. For patients with multiple admissions for bacteremia, only the first admission was included. Medication use was identified from both outpatient prescriptions and medications given during the hospital stay. Charlson and Elixhauser comorbidity scores were defined using diagnosis codes.^[@bibr14-2050312118801707]^

Using pharmacy claims, we identified prevalent statins users demonstrating adherence to their statin therapy, which was defined as patients who, irrespective of their statin initiation time, had at least 90 days of continuous statin exposure (i.e. atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin) in the 90 days prior to hospitalization. In terms of adherence measures, the proportion of days covered was therefore 100% for all included patients, at least 90 days of supply dispensed in the 90 days prior to admission. The proportion of days covered (PDC) of ⩾80% is commonly considered as good adherence for statins.^[@bibr19-2050312118801707],[@bibr20-2050312118801707]^ Statin exposure was further categorized as statin continuation, with at least 5 days of statin therapy after admission, and non-continuation after admission. Inpatient mortality was defined as death occurring during the hospital stay.

To identify baseline differences between the statin continuation and non-continuation groups, we reviewed demographic and clinical data including current and prior comorbidities.^[@bibr14-2050312118801707]^ For categorical variables, if the assumptions for the chi-square test were not met, the Fisher's exact test was utilized. For continuous variables, the non-parametric Wilcoxon Rank Sum test was used.

We developed a propensity score for statin continuation versus non-continuation. The propensity score was therefore the predicted probability of statin therapy continuation, as calculated from the baseline covariates included in an unconditional logistic regression model which was built with manual backward elimination.^[@bibr21-2050312118801707][@bibr22-2050312118801707]--[@bibr23-2050312118801707]^ Patients from the statin continuation and non-continuation groups were stratified by propensity score quintile to achieve homogeneity between exposure groups within quintiles of the predicted probability of statin continuation.^[@bibr24-2050312118801707]^ To evaluate the association of continued statin use and in-hospital mortality, we used a Cox proportional hazards model. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC) and statistical significance was considered a p-value of ⩽0.05. This study was reviewed and approved as exempt by the University of Rhode Island's Institutional Review Board.

Results {#section7-2050312118801707}
=======

We identified 633 patients who met our inclusion and exclusion criteria ([Figure 1](#fig1-2050312118801707){ref-type="fig"}). This included 232 patients with statin continuation and 401 with non-continuation. In comparing the statin continuation and non-continuation groups ([Table 1](#table1-2050312118801707){ref-type="table"}), age (median 62 vs 61 years) and gender (43% vs 44% females) were similar. The median Charlson comorbidity index during admission (2.0 vs 2.0, p = 0.57; [Table 2](#table2-2050312118801707){ref-type="table"}) and during the 6 months prior to admission (3.0 vs 3.0, p = 0. 97) was the same in both the groups. Admission from the emergency room occurred for 97% of patients with statin continuation and 95% with non-continuation (p = 0.29). Marital status, race, region, and admitting physician specialty were also similar between the statin continuation versus non-continuation groups. Simvastatin (53.2%) and atorvastatin (33.8%) were the most commonly used statins. Inpatient mortality was significantly lower (2.59% vs 10.97%, p = 0.0002) and length of stay was higher (median 6.0, interquartile range (IQR) 5.0--9.0 vs 5.0 days, IQR 3.0--9.0, p \< 0.0001) in those continuing statins compared with those not continuing. The final propensity score model c-statistic was 0.88, suggesting a strong model for predicting the probability of statin continuation.^[@bibr23-2050312118801707]^ Among bacteremic patients with adherent statin use prior to admission, the propensity score adjusted Cox proportional hazards regression model evaluating time to inpatient mortality demonstrated significantly lower inpatient mortality among those continuing statin therapy (hazard ratio (HR) 0.25, 95% CI 0.08--0.79) compared with those not continuing after admission.

![Study cohort identification.](10.1177_2050312118801707-fig1){#fig1-2050312118801707}

###### 

Demographic and hospitalization-related characteristics among adherent statin users prior to admission.

![](10.1177_2050312118801707-table1)

  Characteristics                             Statin continuation (N = 232)   Non-continuation (N = 401)   p value            
  ------------------------------------------- ------------------------------- ---------------------------- --------- -------- --------
  Age (years)                                 62                              55--76                       61        56--68   0.1928
  Gender                                      0.6749                                                                          
   Female                                     99                              42.67                        178       44.39    
   Male                                       133                             57.33                        223       55.61    
  Race                                        0.8387                                                                          
   Black                                      17                              7.3                          34        8.5      
   Other                                      33                              14.2                         53        13.2     
   White                                      182                             78.5                         314       78.3     
  Census region                               0.1168                                                                          
   East North Central                         45                              19.4                         57        14.21    
   East South Central                         5                               2.16                         5         1.25     
   Middle Atlantic                            10                              4.31                         21        5.24     
   Mountain                                   13                              5.60                         22        5.49     
   New England                                7                               3.02                         5         1.25     
   Pacific                                    27                              11.64                        32        7.98     
   South Atlantic                             64                              27.59                        153       38.15    
   West North Central                         27                              11.64                        45        11.22    
   West South Central                         34                              14.66                        61        15.21    
  Admission Type                              0.2932                                                                          
   Emergency                                  225                             96.98                        382       95.26    
   Non-emergency                              7                               3.02                         19        4.74     
  Admitting physician facility                0.7205                                                                          
   Intensive care/surgery                     8                               3.45                         18        4.49     
   Medicine                                   93                              40.09                        167       41.65    
   Other                                      131                             56.47                        216       53.87    
  Diagnosis-related group (DRG) description   0.1988                                                                          
   Non-ventilation                            224                             96.55                        378       94.26    
   Ventilation                                8                               3.45                         23        5.74     
  Hospital admission year                     0.2553                                                                          
   2010                                       41                              17.67                        85        21.20    
   2011                                       95                              40.95                        143       35.66    
   2012                                       96                              41.38                        173       43.15    

Data are median and interquartile range (IQR) or number and percent of patients.

###### 

Clinical characteristics and health service utilization among adherent statin users prior to admission.

![](10.1177_2050312118801707-table2)

  Characteristics                                              Statin continuation (N = 232)   Non-continuation (N = 401)   p value           
  ------------------------------------------------------------ ------------------------------- ---------------------------- --------- ------- ----------
  Comorbidities (during admission)                                                                                                            
   Charlson score (median and IQR)                             2                               1--4                         2         0--3    0.5708
   Elixhauser score (median and IQR)                           4                               3--6                         4         3--6    0.3973
   Chronic renal disease                                       61                              26.29                        78        19.45   0.0451
   Coagulation and hemorrhagic disorders                       27                              11.64                        84        20.95   0.0030
   Coagulopathy                                                25                              10.78                        75        18.70   0.0084
   Congestive heart failure nonhypertensive                    64                              27.59                        60        14.96   0.0001
   Coronary atherosclerosis and other heart diseases           87                              37.50                        115       28.68   0.0218
   Diabetes mellitus with complication                         61                              26.29                        69        17.21   0.0064
   Dyslipidemia including hyperlipidemia                       161                             69.40                        208       51.87   \<0.0001
   Infective arthritis                                         15                              6.47                         11        2.74    0.0230
   Liver disease                                               12                              5.17                         47        11.72   0.0063
   Malignant neoplasm                                          6                               2.59                         54        13.47   \<0.0001
   Metastatic cancer                                           3                               1.29                         30        7.48    0.0003
   Mild liver disease                                          11                              4.74                         40        9.98    0.0197
   Obesity                                                     69                              29.74                        83        20.70   0.0103
   Poisoning by medication and drugs                           20                              8.62                         69        17.21   0.0027
   Solid tumor without metastasis                              5                               2.16                         49        12.22   \<0.0001
   Weight loss                                                 22                              9.48                         68        16.96   0.0095
  Medication use (during admission)                                                                                                           
   Anti-hypertensive medication                                207                             89.22                        274       68.33   \<0.0001
  Comorbidities (6 months prior to admission)                                                                                                 
   Charlson score (median and IQR)                             3                               1--5                         3         2--6    0\. 9720
   Elixhauser score (median and IQR)                           6                               5--9                         5         3--9    0.7992
   History of any cancer                                       35                              15.09                        102       25.44   0.0023
   History of chronic kidney disease                           47                              20.26                        57        14.21   0.048
   History of condition with dizziness or vertigo              32                              13.79                        25        6.23    0.0014
   History of dyslipidemia including hyperlipidemia            175                             75.43                        263       65.59   0.0097
   History of history of other Immunocompromise                14                              6.03                         46        11.47   0.0244
   History of maintenance chemotherapy radiotherapy            8                               3.45                         43        10.72   0.0012
   History of malignant neoplasm                               24                              10.34                        76        18.95   0.0042
   History of metastatic cancer                                7                               3.02                         37        9.23    0.0031
   History of other and ill-defined cerebrovascular diseases   15                              6.47                         12        2.99    0.0372
   History of other eye disorder                               27                              11.64                        28        6.98    0.0451
   History of solid tumor without metastasis                   24                              10.34                        74        18.45   0.0066
  Medication use history (6 months prior to admission)                                                                                        
   History of diabetic medication                              74                              31.9                         112       27.93   0.0081
   History of anti-hypertensive medication                     199                             85.78                        317       79.05   0.0357

Data are median and interquartile range (IQR) or number and percent of patients.

Discussion {#section8-2050312118801707}
==========

In this retrospective cohort study among privately insured patients with bacteremia, we observed higher survival among the statin continuation group compared with the non-continuation group. These results support statin continuation through the period of inflammation, as the inflammatory response has been found to be lower among patients taking statins around the time the infection develops.^[@bibr25-2050312118801707],[@bibr26-2050312118801707]^ The specific mechanism by which mortality is reduced among statin users with bacteremic infections still remains undefined, however, a proposed mechanism has been the moderation of the overall inflammatory response.^[@bibr27-2050312118801707]^ Other previously observed anti-inflammatory effects with statins have included lowering of C-reactive protein (CRP), chemokine release (MCP-1, RANTES), cytokines (IL-1β, TNF α, IL-6, IL-8), and adhesion molecules (P-selectin, VLA 4, CD11a, CD11b, CD18).^[@bibr28-2050312118801707],[@bibr29-2050312118801707]^ Statins may also have a direct antimicrobial effect,^[@bibr30-2050312118801707]^ and possible antibacterial activity of statins against a variety of pathogens may be attributed to their ability to suppress cell growth, and to promote apoptosis.^[@bibr31-2050312118801707][@bibr32-2050312118801707]--[@bibr33-2050312118801707]^

Contrary to our findings, a recent randomized controlled trial (RCT) did not observe benefits of statin continuation on inflammatory parameters and sepsis among adherent statin users.^[@bibr34-2050312118801707]^ However, the aforementioned study has several methodological issues as pointed out in a correspondence by Bostock and Vizcaychipi,^[@bibr35-2050312118801707]^ including a vague primary endpoint, lack of information regarding previous statin therapy duration, and use of the Mann--Whitney test to evaluate the matched groups. The limitations of a number of previous studies evaluating protective effects of statins were (a) control for few confounders,^[@bibr2-2050312118801707],[@bibr7-2050312118801707],[@bibr10-2050312118801707],[@bibr27-2050312118801707],[@bibr36-2050312118801707]^ (b) lack of information about pre-hospitalization medication use,^[@bibr10-2050312118801707],[@bibr36-2050312118801707],[@bibr37-2050312118801707]^ (c) combined incident and adherent statin use,^[@bibr2-2050312118801707],[@bibr27-2050312118801707],[@bibr37-2050312118801707]^ and (d) combined pre-hospital and post-hospital use.^[@bibr37-2050312118801707],[@bibr38-2050312118801707]^ These limitations may explain the conflicting findings between studies in regard to the impact of statin use on mortality among patients with infections.

In terms of contrasting results between studies assessing the effects of statin continuation, a prospective cohort study conducted in Spain evaluated the survival benefits with statin use in *S. aureus* bacteremic (SAB) patients with at least 30 days prior statin use and continuation until SAB diagnosis, and did not observe significant protective effect of statins on 30-day mortality (odds ratio (OR)  =  0.35; 95% CI: 0.10--1.23; p  =  0.10).^[@bibr4-2050312118801707]^ Conversely, a recent multicenter RCT conducted among 250 critically ill patients with severe sepsis (123 statins, 127 placebo) reported a significantly lower 28-day mortality rate in the adherent statin continuation group compared with the placebo group (5% vs 28%; p = 0.01).^[@bibr39-2050312118801707]^ A retrospective cohort study conducted at a Veterans Affairs Medical Center in Washington among bacteremic patients, identified a therapeutic benefit with statin continuation (n = 35 vs 353, adjusted OR 0.13, 95% CI 0.02--0.99) compared with non-statin users.^[@bibr7-2050312118801707]^

The results of this study have potential limitations. In our primary analysis, we evaluated adherent statin users, potentially leading to healthy user bias. We used time-varying analytic methods to mitigate the impact of survival bias. However, in the comparison group, one death was observed within the first 5 days of admission, and had this patient been excluded, the HR may have been closer to 1. Furthermore, the sample size of our study was small and we could not study the protective effects of each statin separately due to the small numbers. The effect of statins on inpatient mortality in patients with sepsis may be different for individual statins.^[@bibr40-2050312118801707]^ We also could not assess the dose-dependent effects, changes in statin therapy (drug or dose) prior to admission, at admission, or during the admission, or the effects of adherence due to low sample sizes. In our review of statin doses, dispensing quantity in incident users mostly reflected moderate to high doses. As we used an administrative claims database for our analysis, we assumed outpatient statin exposure to be equivalent to filling a prescription. Furthermore, there is a possibility of statins having a different impact on clinical outcomes based on the causative pathogen, since the mechanism of action is not exactly known and it may vary for different pathogens. Microbiology data was not available for a potential causative pathogen, but we identified organisms using ICD-9 codes, where available. Bacteremic treatment varies by organism type and we were only able to use general inclusion criteria of having received an antibiotic which may be used for bacteremia.^[@bibr15-2050312118801707][@bibr16-2050312118801707][@bibr17-2050312118801707]--[@bibr18-2050312118801707]^ Since we only evaluated a general bacteremic population, our results may not be generalized to pathogen-specific bacteremias. Despite using propensity scores to control for confounding, we could not control for unmeasured confounding. Specifically, bacteremia severity scores and bacteremia source were not available from the data source, although we did control for ventilation status and sepsis severity using diagnosis-related groups (DRG).

In conclusion, our retrospective cohort study quantified the effect of adherent statin continuation on clinical outcomes such as inpatient mortality and hospital length of stay among bacteremic patients in a real-world clinical population. We observed significant reduction in inpatient morality among adherent statin continuation for at least the first few days after hospitalization compared with non-continuation during admission. Our results possibly hint at the necessity of statin exposure through the period of inflammation development as the inflammatory response has been found to be decreasing among patients consuming statins at the same time as developing infection.^[@bibr25-2050312118801707],[@bibr26-2050312118801707]^ Further unaddressed questions related to this research question include appropriate statin exposure time and duration needed for the maximum clinical benefits, and differences in the magnitude of each statin's protective effects.
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